Retatrutide vs Cagrilintide

A triple agonist of GIP, GLP-1, and glucagon receptors in late-stage clinical trials, producing ~24% weight loss at 48 weeks in Phase 2 — the largest effect size of any weight-loss pharmaceutical to date.

A long-acting amylin analogue developed by Novo Nordisk. On its own it produces modest weight loss; paired with semaglutide (CagriSema), it exceeds tirzepatide in trials.

Retatrutide simultaneously activates three incretin/metabolic receptors. The addition of glucagon agonism is thought to increase energy expenditure, complementing the appetite suppression driven by GIP and GLP-1.

Cagrilintide activates amylin and calcitonin receptors, delaying gastric emptying and suppressing appetite through a mechanism complementary to GLP-1 receptor agonism.

Phase 2 used 1–12 mg weekly; optimal dose pending Phase 3

2.4 mg subcutaneous weekly (matched to semaglutide)

~6 days

~7 days

Subcutaneous once weekly

Subcutaneous

investigational

investigational

Not yet listed

Not yet listed